Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 355
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
10/22/2008
 
First Published:
7/1/1999
1.
Phase II/III Study of Standard and Novel Conditioning Therapy and Allogeneic Blood or Marrow Transplantation in Patients With Severe Aplastic Anemia or Hematologic Malignancy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Active
4 to 70
Other
RPCI-RP-9815
NCI-V99-1527, NCT00003816, RP 98-15
2.
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Active
12 to 55
Pharmaceutical / Industry
GC P#02.01.001
NCT00469729
Last Modified:
6/9/2008
 
First Published:
9/26/2007
3.
Phase II/III Study of Disease-Specific High-Dose Conditioning Regimens Followed by Autologous Stem Cell Transplantation (Single or Tandem) in Patients With Hematologic Malignancies or Solid Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Active
4 and over
NCI
RPCI-I-72806
I 72806, NCT00536601
4.
In-Vivo Activated T-Cell Depletion to Prevent GVHD
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Supportive care, Treatment
Active
18 to 75
Other
0705-20 IUCRO-0196
NCT00594308
Last Modified:
10/21/2008
 
First Published:
12/23/2003
5.
Phase III Randomized Study of Nonmyeloablative Conditioning Comprising Low-Dose Total Body Irradiation With Versus Without Fludarabine Followed By HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies at Low or Moderate Risk For Graft Rejection
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
Under 75
NCI
FHCRC-1813.00
5666, NCT00075478
Last Modified:
9/26/2008
 
First Published:
2/20/2004
6.
Phase III Randomized Study of Salvage Chemotherapy Comprising Dexamethasone, Cisplatin, and Gemcitabine Versus a Standard Platinum-Based Regimen (Dexamethasone, Cisplatin, and High-Dose Cytarabine) Before Autologous Stem Cell Transplantation and With or Without Maintenance Rituximab in Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
16 to 65
Other
CAN-NCIC-LY12
NCT00078949, LY12
Last Modified:
7/1/2008
 
First Published:
3/24/2004
7.
Phase III Randomized Study of Rituximab, Ifosfamide, Carboplatin, and Etoposide Versus Rituximab, Dexamethasone, Cytarabine, and Cisplatin as Induction Therapy Followed By High-Dose Consolidation Chemotherapy and Autologous Stem Cell Transplantation With Versus Without Rituximab as Maintenance Therapy in Patients With Relapsed or Refractory CD20-Positive Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 to 65
NCI
MSKCC-03139
CORAL-50-03B, NCT00137995
8.
A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Pharmaceutical / Industry
CCBX001-049
NCT00078598
9.
Gemcitabine, Dexamethasone and Cisplatin Versus Dexamethasone, Cytarabine, Cisplatin in Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
16 to 65
Pharmaceutical / Industry
7581
NCT00089817
Last Modified:
8/21/2008
 
First Published:
12/22/2004
10.
Phase III Randomized Study of Pixantrone Versus Other Chemotherapeutic Agents as Third-Line Single Agent Therapy in Patients With Relapsed Aggressive Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
NCI, Pharmaceutical / Industry
UCLA-0406049-01
CTI-PIX301, NCT00101049
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute